DYNDyne Therapeutics, Inc.

$3B

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$700,000

Operating Income

-$59M

Net Income

-$59M

EPS (Diluted)

$-1.24

Cash Flow

Operating Cash Flow

-$47M

Free Cash Flow

-$48M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$353M

Total Liabilities

$11M

Stockholders' Equity

$342M

Cash & Equivalents

$301M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$700,000	-$271,000	-158.3%
Operating Income	-$59M	-$14M	-324.2%
Net Income	-$59M	-$14M	-333.9%

DYN FY 2020 Earnings — Dyne Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena